To investigate the immune response, specifically the antibody response and the complement system, in patients with post-COVID syndrome, focusing on the roles of secretory IgA and complement components.
Key Findings:
Increased anti-Nucleocapsid sIgA levels in post-COVID syndrome patients compared to controls, suggesting heightened mucosal immune response.
Reduced C3 levels in post-COVID syndrome patients, indicating complement consumption, which may contribute to immune dysregulation.
No significant difference in CH50 levels, but a negative correlation between serum anti-Nucleocapsid IgG and FH/CH50 in reinfected vaccinated patients, indicating potential implications for vaccine efficacy.
Combining anti-Nucleocapsid sIgA and C3 levels improved discrimination between patients and controls, highlighting their potential as biomarkers.
Interpretation:
Elevated sIgA and reduced C3 levels may indicate ongoing immune dysregulation in post-COVID syndrome, suggesting potential biomarkers for the condition and avenues for targeted therapies.
Limitations:
Findings require validation in independent cohorts to confirm generalizability.
Study focused on a specific population from Comunidad de Madrid, which may limit applicability to other demographics.
Conclusion:
Salivary anti-Nucleocapsid IgA and C3 consumption may serve as candidate biomarkers for post-COVID syndrome, emphasizing the complement system's critical role in its pathophysiology and potential therapeutic targets.
by Zhiwen Hai, Weihua Yang, Azam Ghazi, Amalia Buitrago, Patricia Marín-García, Isabel G Azcárate, Alba González-Escalada, Nineth Rossi, Javier Benítez-Cruz, Iván Estévez-Benito, Agustín Tortajada, José R. Regueiro, José M. Bautista, Narcisa Martinez-Quiles
